Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Allos Therapeutics Inc (ALTH)
since 2010 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Allos Therapeutics Inc.
Table 2 shows the detailed insider transactions.
This company's CIK number is 1097264.
Total stock buying since 2010: $238,167,242.
Total stock sales since 2010: $529,016.
Total stock option exercises since 2010: $16,534.
Table 3. Detailed insider trading at Allos Therapeutics Inc (ALTH)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2012-09-05 | Sapphire Acquisition Sub, Inc. (10% Owner) | Buy | 130,854,840 | 1.82 | 238,155,808 |
| 2012-07-11 | Schick Michael E (VP, Sales and Marketing) | Sale | 697 | 1.78 | 1,241 |
| 2012-04-27 | Morris Charles Q (Chief Medical Officer) | Sale | 7,970 | 1.81 | 14,425 |
| 2012-04-27 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Buy | 1,104 | 1.22 | 1,342 |
| 2012-03-01 | Schick Michael E (VP, Sales and Marketing) | Sale | 3,960 | 1.48 | 5,864 |
| 2012-03-01 | Goldsmith Bruce A (SVP, Corporate Development) | Sale | 4,473 | 1.50 | 6,691 |
| 2012-03-01 | Graboyes Marc H (SVP, General Counsel) | Sale | 9,635 | 1.48 | 14,259 |
| 2012-03-01 | Clark David C (VP, Finance) | Sale | 3,385 | 1.50 | 5,074 |
| 2012-03-01 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Sale | 3,025 | 1.50 | 4,522 |
| 2012-03-01 | Berns Paul L (Chief Executive Officer) | Sale | 21,532 | 1.48 | 31,824 |
| 2012-02-29 | Schick Michael E (VP, Sales and Marketing) | Sale | 3,894 | 1.52 | 5,934 |
| 2012-02-29 | Goldsmith Bruce A (SVP, Corporate Development) | Sale | 4,505 | 1.52 | 6,870 |
| 2012-02-29 | Morris Charles Q (Chief Medical Officer) | Sale | 10,155 | 1.52 | 15,476 |
| 2012-02-29 | Graboyes Marc H (SVP, General Counsel) | Sale | 9,425 | 1.52 | 14,363 |
| 2012-02-29 | Clark David C (VP, Finance) | Sale | 3,388 | 1.52 | 5,163 |
| 2012-02-29 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Sale | 3,031 | 1.52 | 4,622 |
| 2012-02-29 | Berns Paul L (Chief Executive Officer) | Sale | 21,163 | 1.52 | 32,231 |
| 2012-02-24 | Goldsmith Bruce A (SVP, Corporate Development) | Sale | 575 | 1.54 | 888 |
| 2012-02-24 | Graboyes Marc H (SVP, General Counsel) | Sale | 1,380 | 1.54 | 2,125 |
| 2012-02-24 | Clark David C (VP, Finance) | Sale | 595 | 1.55 | 922 |
| 2012-02-24 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Sale | 1,469 | 1.55 | 2,276 |
| 2012-02-24 | Berns Paul L (Chief Executive Officer) | Sale | 4,350 | 1.55 | 6,742 |
| 2012-02-23 | Schick Michael E (VP, Sales and Marketing) | Sale | 1,645 | 1.58 | 2,599 |
| 2012-02-23 | Goldsmith Bruce A (SVP, Corporate Development) | Sale | 2,500 | 1.58 | 3,957 |
| 2012-02-23 | Graboyes Marc H (SVP, General Counsel) | Sale | 3,950 | 1.58 | 6,252 |
| 2012-02-23 | Clark David C (VP, Finance) | Sale | 1,460 | 1.57 | 2,290 |
| 2012-02-23 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Sale | 4,484 | 1.58 | 7,084 |
| 2012-02-23 | Berns Paul L (Chief Executive Officer) | Sale | 9,100 | 1.56 | 14,196 |
| 2011-12-30 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Buy | 1,173 | 1.21 | 1,415 |
| 2011-11-16 | Schick Michael E (VP, Sales and Marketing) | Sale | 140 | 1.43 | 200 |
| 2011-11-16 | Goldsmith Bruce A (SVP, Corporate Development) | Sale | 300 | 1.43 | 429 |
| 2011-11-16 | Clark David C (VP, Finance) | Sale | 125 | 1.43 | 178 |
| 2011-11-16 | Berns Paul L (Chief Executive Officer) | Sale | 450 | 1.43 | 643 |
| 2011-11-15 | Schick Michael E (VP, Sales and Marketing) | Sale | 8,033 | 1.44 | 11,575 |
| 2011-11-15 | Goldsmith Bruce A (SVP, Corporate Development) | Sale | 12,465 | 1.45 | 18,011 |
| 2011-11-15 | Morris Charles Q (Chief Medical Officer) | Sale | 17,829 | 1.44 | 25,727 |
| 2011-11-15 | Graboyes Marc H (SVP, General Counsel) | Sale | 14,494 | 1.44 | 20,900 |
| 2011-11-15 | Clark David C (VP, Finance) | Sale | 5,438 | 1.45 | 7,863 |
| 2011-11-15 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Sale | 26,100 | 1.45 | 37,714 |
| 2011-11-15 | Berns Paul L (Chief Executive Officer) | Sale | 31,817 | 1.46 | 46,516 |
| 2011-07-11 | Schick Michael E (VP, Sales and Marketing) | Sale | 730 | 2.06 | 1,505 |
| 2011-06-30 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Buy | 772 | 1.82 | 1,404 |
| 2011-04-27 | Morris Charles Q (Chief Medical Officer) | Sale | 9,800 | 2.84 | 27,822 |
| 2011-03-17 | Berns Paul L (Chief Executive Officer) | Option Ex | 2,500 | 3.14 | 7,850 |
| 2011-02-24 | Graboyes Marc H (SVP, General Counsel) | Sale | 1,410 | 3.12 | 4,406 |
| 2011-02-24 | Clark David C (VP, Finance) | Sale | 557 | 3.12 | 1,739 |
| 2011-02-24 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Sale | 1,469 | 3.20 | 4,700 |
| 2011-02-24 | Berns Paul L (Chief Executive Officer) | Sale | 4,255 | 3.12 | 13,292 |
| 2011-02-23 | Schick Michael E (VP, Sales and Marketing) | Sale | 1,570 | 3.25 | 5,105 |
| 2011-02-23 | Graboyes Marc H (SVP, General Counsel) | Sale | 3,800 | 3.24 | 12,315 |
| 2011-02-23 | Clark David C (VP, Finance) | Sale | 1,365 | 3.25 | 4,438 |
| 2011-02-23 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Sale | 4,484 | 3.23 | 14,487 |
| 2011-02-23 | Berns Paul L (Chief Executive Officer) | Sale | 9,193 | 3.25 | 29,877 |
| 2010-12-31 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Buy | 333 | 3.92 | 1,304 |
| 2010-06-30 | Graboyes Marc H (SVP, General Counsel) | Buy | 913 | 5.21 | 4,756 |
| 2010-06-30 | Bennett Bruce K Jr (VP, Pharmaceutical Operations) | Buy | 233 | 5.21 | 1,213 |
| 2010-05-10 | Clark David C (VP, Finance) | Sale | 3,085 | 7.03 | 21,684 |
| 2010-05-10 | Clark David C (VP, Finance) | Option Ex | 3,085 | 2.81 | 8,684 |
Insider trading activities including stock purchases, stock sales, and option exercises
of ALTH listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Allos Therapeutics Inc (symbol ALTH,
CIK number 1097264) see
the Securities and Exchange Commission (SEC) website.